在过去的十年中，多靶点抗癌药物的兴趣，包括异金属化合物，在相当程度上增加了。相比于单个金属片段，异金属物种在多种金属配对的情况下显示出更好的疗效和物理化学性质。到2018年，几种化合物已经成为抗顺铂耐药癌症的有希望的候选药物。在这里，我们总结了过去四年（2018年7月至2022年7月）对该主题的研究贡献。特别是，我们重点介绍了五篇文章，报告了五组化合物的体内活性和初步作用机制。从这个选择中，我们进一步介绍了两个基于Pt（IV）-Gd（III）和Ti（IV）-Au（I）金属组合的化合物家族，因为它们具有临床转化的潜力。版权所有©2022 Elsevier Ltd.

Over the past decade, interest on multitarget anticancer drugs -including heterometallic compounds-has increased considerably. Heterometallic species display improved efficacy and physicochemical properties compared to the individual metallic fragments for a variety of metal pair combinations. By 2018, several compounds had emerged as promising candidates against cisplatin resistant cancers. Here, we summarize research contributions to this topic over the past four years (July 2018-July 2022). In particular, we highlight five articles reporting on the in vivo activity and preliminary mechanisms of action for five groups of compounds. From this selection, we further feature two families of compounds based on Pt(IV)-Gd(III) and Ti(IV)-Au(I) metal combinations, given their potential for clinical translation.Copyright © 2022 Elsevier Ltd. All rights reserved.